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NF-κB inhibition rescues cardiac function
by remodeling calcium genes in a Duchenne
muscular dystrophy model
Jennifer M. Peterson1,2,3,7, David J. Wang1,3,8, Vikram Shettigar2,3,4, Steve R. Roof2,3,4,9, Benjamin D. Canan2,3,4,
Nadine Bakkar1,2,3,10, Jonathan Shintaku 1,2,3,11, Jin-Mo Gu1,2,3,12, Sean C. Little2,3,4,13, Nivedita M. Ratnam1,3,
Priya Londhe1,2,3,14, Leina Lu5,15, Christopher E. Gaw 3,16, Jennifer M. Petrosino2,3, Sandya Liyanarachchi1,3,
Huating Wang5, Paul M.L. Janssen2,3,4, Jonathan P. Davis2,3,4, Mark T. Ziolo2,3,4, Sudarshana M. Sharma 6 &
Denis C. Guttridge1,2,3,8

Duchenne muscular dystrophy (DMD) is a neuromuscular disorder causing progressive
muscle degeneration. Although cardiomyopathy is a leading mortality cause in DMD patients,
the mechanisms underlying heart failure are not well understood. Previously, we showed that
NF-κB exacerbates DMD skeletal muscle pathology by promoting inﬂammation and impairing
new muscle growth. Here, we show that NF-κB is activated in murine dystrophic (mdx)
hearts, and that cardiomyocyte ablation of NF-κB rescues cardiac function. This physiological
improvement is associated with a signature of upregulated calcium genes, coinciding with
global enrichment of permissive H3K27 acetylation chromatin marks and depletion of the
transcriptional repressors CCCTC-binding factor, SIN3 transcription regulator family member
A, and histone deacetylase 1. In this respect, in DMD hearts, NF-κB acts differently from its
established role as a transcriptional activator, instead promoting global changes in the
chromatin landscape to regulate calcium genes and cardiac function.
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ystrophin is a large cytoplasmic protein that provides
structural integrity to muscle. Mutations in the dystrophin gene result in X-linked dilated cardiomyopathy,
Becker muscular dystrophy, and Duchenne muscular dystrophy
(DMD)1–3. Loss of dystrophin protein has also been reported in
acquired heart failure, myocardial infection, and myocardial
infarction patients, as well as in animal models of myocardial
injury and infection4–8. This suggests that downstream effects of
dystrophin loss is a common link in cardiomyopathy. In DMD
patients and animal models, limb, diaphragm, and cardiac muscles are all progressively affected, resulting in loss of ambulation,
respiratory distress, and cardiomyopathy, respectively. Cardiac
involvement in patients begins in the second to third decade of
life and is a leading cause of morbidity and mortality9. These
patients commonly develop cardiomyopathy with arrhythmias,
and animal studies show that calcium dysregulation is a causative
factor in the pathology10,11. However, the molecular mechanisms
underlying disease development in these patients have not been
elucidated, and the acute cardiac events that lead to an accumulation of cardiac damage are not well understood.
NF-κB is ubiquitously expressed and functions in cell survival,
apoptosis, growth, and differentiation12. Our group and others
have shown that NF-κB signaling regulates both physiological
(differentiation, growth, and metabolism) and pathophysiological
(cachexia, atrophy, and dystrophy) aspects of skeletal muscle
biology13–16. The most common NF-κB complex is the p50/p65
heterodimer, with p65 containing the transactivation domain
required to mediate transcriptional activation. NF-κB is held in
tight regulation by the inhibitory protein IκB. The upstream IKK
kinase (inhibitor of NF-κB kinase) is comprised of two catalytic
subunits, IKKα and IKKβ, and a regulatory subunit, IKKγ/
NEMO. During classical NF-κB activation, IKK is phosphorylated, and in turn phosphorylates IκB. This phosphorylation
causes ubiquitination and subsequent degradation of IκB by the
26S proteasome pathway. Degradation of IκB unmasks a nuclear
localization site, allowing NF-κB to translocate to the nucleus,
bind consensus sites on target genes, and activate gene expression.
Studies show that classical NF-κB promotes skeletal muscle
pathology in the mdx murine DMD model17–21. Inhibiting NFκB, either globally by ablating one copy of the p65 gene or conditionally by removing IKKβ alleles in skeletal muscle ﬁbers or
myeloid cells, improved dystrophic pathology18. Cell or gene
therapy designed to target p65 or IKK, respectively, were also
effective in protecting mdx skeletal muscle19–21. Mechanistically,
inhibiting NF-κB improved the histology and function of dystrophic limb and diaphragm muscles by enhancing the regenerative potential of muscle stem cells and reducing muscle
damage from inﬂammatory cells18. These ﬁndings laid the
foundation for inhibiting NF-κB as a therapy to treat DMD.
As a therapeutic, we and others have examined the potential of
using the Nemo Binding Domain (NBD) peptide, which is a speciﬁc
NF-κB inhibitor22. In mdx mice, NBD treatment rescued diaphragm function and improved overall muscle endurance17,18.
Histologically, NBD reduced inﬂammation and enhanced regeneration in limb muscles, indicating dystrophic muscles were stabilized. In the Golden Retriever DMD model (GRMD), NBD
administration improved hind-limb function, posture, and skeletal
muscle histopathology23. While encouraged that such results might
translate to improved ambulation and respiratory function in DMD
patients, we realized that further development of an NF-κB inhibitor would require investigation into its effects on dystrophic
cardiac muscle. In a preliminary study, we showed that NBD
administration rescued in vitro cardiac function in the severe dystrophin/utrophin double knockout murine DMD model24. These
results indicated that NF-κB contributes to dystrophic cardiac disease, but how it promotes this pathology remains unknown.
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In this study, we set out to understand the mechanism by
which NF-κB regulates cardiac dysfunction in mdx mice. We
discover that unlike the typical function of NF-κB as an inducer
of gene expression, NF-κB ablation in mdx cardiomyocytes causes
global permissive chromatin remodeling on enhancers of calcium
genes, which in turn permits increased gene expression and an
overall improvement in cardiac function.
Results
NF-κB promotes cardiac dysfunction in mdx mice. Cardiomyopathy develops progressively over the lifespan of the mdx
mouse. From a young age (8–10 weeks), only ex vivo cardiomyocyte dysfunction is detected25,26. Histological abnormalities
are apparent by 7 months27, and by 10–12 months, dysfunction
in vivo is detectable by echocardiogram28–30. By 2 years, severe
cardiomyopathy is apparent31. Based on these time points, we
asked if NF-κB activation occurs early in the disease process. NFκB DNA binding was low in 3-month-old adult wt hearts, and
increased in age matched mdx hearts (Fig. 1a). This activity was
attributable to p65 and p50 (Fig. 1a). Phosphorylation of p65 on
serine 536, which is a marker of NF-κB transcriptional activity,
indicated that NF-κB activation persisted in 1-year-old mdx hearts
(Fig. 1b). To determine the cellular source of NF-κB, we performed immunohistochemistry on cardiac tissue. Results showed
that NF-κB was most prominently localized to mdx cardiomyocyte
nuclei (Fig. 1c and Supplementary Fig. 1A). Together, these results
indicate that NF-κB is active prior to the onset of mdx cardiomyopathy, and persists throughout the disease process.
Since we detected activated NF-κB within cardiomyocytes, we
asked if this signaling was relevant for dystrophic cardiomyopathy by conditionally deleting IKKβ from mdx cardiomyocytes.
Knock-out mice were denoted mdxHRTΔIKKβ, while littermates
with intact NF-κB were designated mdxIKKβf/f. We conﬁrmed that
IKKβ expression was reduced in mdxHRTΔIKKβ hearts (Supplementary Fig. 1B). Then we examined gross differences between wt,
mdxIKKβf/f and mdxHRTΔIKKβ mice. Representative histological
whole hearts sections are included in Supplementary Fig. 1C. By
12–14 months, body weight and heart weight adjusted for tibia
length from both mdxIKKβf/f and mdxHRTΔIKKβ mice were less
than wt, but this difference only reached signiﬁcance in the
mdxHRTΔIKKβ mice (Table 1). These data indicate that cardiomyocyte deletion of IKKβ does not prevent the reduction of body
or heart weight that occurs in aging mdx mice30,32.
In vivo dysfunction has been shown at 10 months in mdx
mice28–30. We asked if deleting NF-κB from mdx cardiomyocytes
resulted in long-term functional changes. To assure we could
detect differences from control mice, echocardiograms were
performed on 13–14 month old mice. While cardiac output was
reduced in mdxIKKβf/f mice, it was restored to wt levels in
mdxHRTΔIKKβ mice (Fig. 1d). Because anesthetized heart rates
were similar between groups (Table 1), stroke volume, which was
also signiﬁcantly compromised in mdxIKKβf/f mice, was restored
to wt values in mdxHRTΔIKKβ mice (Fig. 1e). Ejection fraction was
preserved in mdxIKKβf/f mice (Fig. 1f), suggesting that mdx mice
suffer from diastolic dysfunction with either preserved systolic
function or a compensation that masks systolic dysfunction. A
closer analysis of chambers parameters further supported these
ﬁndings. While systolic diameters and volumes were not
signiﬁcantly altered (Table 1), end diastolic diameters and
volumes were both reduced in mdxIKKβf/f and normalized in
mdxHRTΔIKKβ mice (Fig. 1g,h), indicating that NF-κB deletion
prevented the developed pathology of small cardiac chambers in
mdx mice. Together, data suggest that in mdx cardiomyocytes,
NF-κB activation causes a smaller, stiff left ventricle with
decreased compliance.
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Fig. 1 NF-κB causes heart dysfunction in mdx mice. a EMSA performed on wild-type (wt) and mdx hearts (left panel). Supershift EMSA performed on mdx
hearts using speciﬁc antibodies for p65 and p50, and IgG as a control (Right panel). Arrowheads indicate shifted bands. b Western blots performed on
whole heart lysates and probed for phosphorylated p65-ser536 (phospho-p65), p65, p50, and α-tubulin (used as a loading control). c Representative
images of H&E and phosho-p65 staining prepared from 1-year old heart sections. Boxed regions appear as magniﬁed images in neighboring panels. Scale
bar = 50 μm. d cardiac output, e stroke volume, f ejection fraction (p = 0.686), g end diastolic diameter, and h end diastolic volume assessed by
echocardiogram on 13–14-month-old mice (n = 4 wt; 8 mdxIKKβf/f; 5 mdxHRTΔIKKβ). i End-diastolic pressure volume relationship (EDPVR) assessed by
ventricular pressure-volume relationship analysis on 13–14-month old mice (n = 7 wt; 18 mdxIKKβf/f; 12 mdxHRTΔIKKβ). j Developed force measured from
isolated multicellular cardiac muscles of 7-month old mice in response to β-adrenergic stimulation with isoproterenol (n = 7 wt; 7 mdxIKKβf/f; 9
mdxHRTΔIKKβ; 3 NBD treated (mdx-NBD); p = 0.278). k Relaxation time (RT90) after isoproterenol stimulation in multicellular cardiac muscles (n = same
as J). l, m Ventricular pressure-volume relationship measurements after dobutamine administration on 13–14-month-old mice. l Maximal heart rate (HR)
(n = 5 wt; 8 mdxIKKβf/f; 7 mdxHRTΔIKKβ) and (m) Tau (isovolumetric relaxation) (n = 5 wt; 7 mdxIKKβf/f; 4 mdxHRTΔIKKβ; p = 0.027 but multiple comparisons
test did not detect differences between groups). Data expressed as means ± SEM with bars and plungers and individual data points with dots. *p < 0.05
relative to wt and # p < 0.05 relative to mdxIKKβf/f by d–i, k–m 1-way ANOVA followed by Tukey multiple comparison test where appropriate, j 2-way
repeated measures ANOVA. Main effects for genotype/treatment
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Table 1 Data are expressed as means ± SEM. 1-way ANOVA followed by Tukey multiple comparison test
Parameters
General
Body weight (g)
Heart weight/tibia length (mg mm−1)
Echocardiogram
HR (BPM)
Systolic diameter (mm)
End systolic volume (ml)
Left ventricular mass (mg)
FS (%)
aIndicates

wt
n=6
36.1 ± 0.7
7.5 ± 0.1
n=4
389.8 ± 17.7
2.8 ± 0.2
29.8 ± 4.6
136.2 ± 6.4
31.0 ± 2.7

mdxHRTΔIKKβ
n=8
31.1 ± 1.5a
6.1 ± 0.2 a
n=5
357.0 ± 13.1
2.7 ± 0.2
27.3 ± 3.8
142.8 ± 7.5
32.0 ± 2.4

P value
0.0376
0.0073
0.3666
0.0403
0.0432
0.7911
0.7249

different from wt where multiple comparison test detected differences. HR, (heart rate); FS, (fractional shortening)

To more closely investigate how NF-κB signaling affects
cardiac contractility, we performed left ventricular pressurevolume relationship analysis. End-diastolic pressure volume
relationship was increased in mdxIKKβf/f compared to wt mice
and restored to wt values in mdxHRTΔIKKβ mice (Fig. 1i), whereas
end systolic pressure volume relationship was similar between all
groups (Supplementary Table 1). Additional functional parameters that were not signiﬁcantly altered are also reported in
Supplementary Table 1. These data further support our
echocardiogram results, suggesting that NF-κB signaling in mdx
cardiomyocytes promotes diastolic dysfunction.
We next examined ex vivo cardiac function. We systemically
treated 6-month-old mdx mice with NBD peptide for 1 month
and performed function on multicellular cardiac preparations.
We chose this time because ex vivo histological and functional
cardiac deﬁcits begin to develop at this stage. Age matched mice
from our genetic model were used for comparisons. Although
force values derived from mdxIKKβf/f mice were consistently lower
across all frequencies compared to wt, these differences did not
reach statistical signiﬁcance (Supplementary Fig. 1D). In
comparison, force production was higher in both mdxHRTΔIKKβ
and NBD-treated mdx muscles than in mdxIKKβf/f and wt
muscles. We then assessed the ability of these multicellular
muscles to relax, which affects cardiac diastole. Time from peak
force to 90% relaxation (RT90) trended toward being slower in
mdxIKKβf/f muscles, whereas mdxHRTΔIKKβ and mdx-NBD
muscles showed relaxation times more similar to wt rates
(Supplementary Fig. 1E). One indicator of a failing heart is the
inability to respond to β-adrenergic stimulation33. We tested if
this was dependent on NF-κB signaling. When cardiac muscles
were challenged with increasing doses of the β-adrenergic
stimulant isoproterenol, mdxIKKβf/f cardiac preparations
responded with weak force production characteristic of their
dystrophic phenotype (Fig. 1j)26. These mice were unresponsive
to both low and moderate isoproterenol doses, only responding
with slightly increased force production at high doses. In contrast,
mdxHRTΔIKKβ and NBD-treated mdx cardiac preparations
responded to low isoproterenol doses following a parabolic curve
similar to wt muscles. When we assessed relaxation, in response
to isoproterenol, time from peak force to 90% relaxation (RT90)
was slower in mdxIKKβf/f muscles, whereas mdxHRTΔIKKβ and
NBD-treated mdx cardiac preparations showed an improved
ability to accelerate their relaxation time back to wt levels
(Fig. 1k). Together, these results indicate that pharmacological
inhibition of NF-κB for just 1 month can reverse existing, stress
induced cardiac muscle dysfunction, and that inhibition of NF-κB
systemically and speciﬁcally in cardiomyocytes reverses the
pathological inability of cardiac muscle preparations to respond
to β-adrenergic stimulation.
To further explore the inability of mdx mice to respond to βadrenergic stimulation, and the dependency of this response on
4

mdxIKKβf/f
n=8
33.5 ± 1.1
6.6 ± 0.4
n=8
396.1 ± 21.1
2.2 ± 0.2
16.5 ± 3.1
139.2 ± 4.7
34.2 ± 2.8

cardiomyocyte NF-κB, we challenged mice with the β-adrenergic
agonist dobutamine while performing pressure-volume loop
analysis in vivo. Wt mice responded with a robust increase in
heart rate, while mdxIKKβf/f mice were unable to increase their
heart rates (Fig. 1l). mdxHRTΔIKKβ mice responded with an
increased heart rate, but did not normalize to wt. Isovolumetric
relaxation time (tau) indicated that accelerated relaxation
occurred in wt and mdxHRTΔIKKβ, but not in mdxIKKβf/f mice,
although this did not reach signiﬁcance (Fig. 1m). These data
demonstrate that mdx cardiac muscle have an impaired ability to
relax and are therefore unable to respond to β-adrenergic stress
with heart rate acceleration. Cumulatively, data show that
cardiomyocyte NF-κB impairs cardiac response to β-adrenergic
stress, thus providing the ﬁrst evidence that cardiomyocytederived classical NF-κB signaling plays an instrumental role in
promoting dystrophic cardiac dysfunction. Although we cannot
exclude the possibility that alternative NF-κB is compensating for
the loss of IKKβ and contributing to the improved phenotype,
processing of p100 to p52, as a measure of alternative pathway
activation, was undetectable in the hearts of any of our mice
(Supplementary Fig. 1F).
Cardiomyocyte NF-κB inhibition improves calcium handling
in mdx hearts. Because cardiac stiffness from ﬁbrosis leads to
diastolic dysfunction, and expression of ﬁbrotic genes is increased
at an early age in mdx hearts (Supplementary Fig. 2A), we asked if
NF-κB promoted cardiac ﬁbrosis. Histologically, ﬁbrosis was
comparable in hearts from 1-year-old mdxIKKβf/f and
mdxHRTΔIKKβ mice (Supplementary Fig. 2B, C). This ﬁnding was
consistent with gene expression analysis of the same panel of
ﬁbrotic genes that were elevated in mdx mice (Supplementary
Fig. 2D). Membrane disruption also appeared similar between
groups (Supplementary Fig. 2B). These data led to an intriguing
implication that while cardiomyocyte NF-κB is not required for
development of cardiac ﬁbrosis or myocyte injury in mdx mice, it
still contributes to cardiac dysfunction.
To gain insight into how NF-κB promotes cardiomyocyte
dysfunction, we performed microarray analysis comparing
mdxHRTΔIKKβ to mdxIKKβf/f hearts. Gene Ontology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
annotations identiﬁed genes related to calcium as enriched in the
absence of NF-κB (Fig. 2a). Because of this proposed link between
NF-κB and calcium, we examined calcium transient amplitudes at
the single cell level to determine if gene expression changes
coincided with functional outcomes. Results showed that
calcium transients were reduced in mdxIKKβf/f compared to
wt mice (Fig. 2b). In sharp contrast, calcium transient deﬁcits
were rescued in mdxHRTΔIKKβ cardiomyocytes, indicating that
NF-κB is intrinsically regulating calcium handling in mdx
cardiomyocytes.
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Fig. 2 Cardiomyocyte NF-κB ablation normalizes calcium handling and increases gene expression. a Statistically signiﬁcant gene categories from
microarray analysis identiﬁed using Gene Set Enrichment Analysis. Heatmaps represent genes identiﬁed in annotations. b Calcium transient amplitude
measured from cardiomyocytes isolated from 7–8-month old mice (n = 38 wt; 43 mdxIKKβf/f; 35 mdxHRTΔIKKβ cardiomyocytes). c Depiction of individual
microarray genes that were up- and down-regulated in mdxHRTΔIKKβ relative to mdxIKKβf/f hearts. Genes shown in red are ≥ 1.5-fold upregulated and those
in blue are ≥ 1.5-fold downregulated. d–g qPCR analysis of Slc8a1 expression. RNA isolated from d 6–7-month-old hearts (n = 5 wt; 5 mdxIKKβf/f; 4
mdxHRTΔIKKβ), e mouse embryonic ﬁbroblasts (MEFs) that were wt (p65+/+) or null (p65−/−) for p65 (n = 5). f C2C12 myotubes expressing empty vector
as control (CT) or IκBα super repressor (SR) (n = 6 CT; 8 SR), and g MEFs untreated (CT) or treated with TNF (n = 4). Data expressed as means ± SEM
with bars and plungers and individual data points with dots. *p < 0.05 relative to respective control and #p < 0.05 relative to mdxIKKβf/f by b, d 1-way
ANOVA followed by Tukey multiple comparison test and e–g 2-tailed Student’s t test

We then took a broader look at the overall gene expression
pattern of dystrophic hearts lacking NF-κB to gain a better
understanding for how this factor may be regulating calcium. NFκB dimers containing the p65 subunit are usually thought of as
transcriptional activators. Thus, when bound to consensus DNA
sequences, target gene expression is typically stimulated12.
Accordingly, we anticipated an overall reduction in gene
expression upon deleting NF-κB in cardiomyocytes. Surprisingly,
only 27% of differentially regulated genes (using 1.5-fold cut-off)
were downregulated when NF-κB was deleted, whereas 73% were
upregulated (Fig. 2c). Consistently, the majority of calcium genes
identiﬁed in the GO and KEGG annotations were also
upregulated in mdxHRTΔIKKβ hearts (Fig. 2a). This is in sharp

contrast to microarray results we recently reported from Ras
transformed p65−/− mouse embryonic ﬁbroblasts (MEFs), which
as expected, showed a predominance of down-regulated genes
(89%) compared to p65+/+ cells34, or previous results in TNF
treated HeLa cells, which demonstrated a similar predominance
of NF-κB dependent upregulated genes35. Thus, our ﬁndings
reveal a previously unappreciated functional role for NF-κB as a
global repressor in mdx hearts.
Next, we sought to understand how NF-κB functions to repress
calcium genes. We observed that differential expression was
subtle, suggesting that small changes from multiple genes, rather
than a large change from a single gene, might be responsible for
improvements in calcium handling in the absence of NF-κB. We
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searched for candidate genes that were both upregulated in
mdxHRTΔIKKβ hearts and associated with calcium. One gene that
ﬁt these criteria was the solute carrier family 8 (sodium/calcium
exchanger), member 1, (Slc8a1 gene that codes for the NCX1
protein). NCX1 is a transmembrane channel protein that plays a
role in maintaining calcium homeostasis in multiple cell types
including muscle36. Quantitative RT-PCR conﬁrmed Slc8a1
upregulation in mdxHRTΔIKKβ compared to mdxIKKβf/f hearts
(Fig. 2d), suggesting this gene is negatively regulated by NF-κB.
This regulation was not restricted to cardiac tissue, since similar
upregulation occurred in p65−/− compared to p65+/+ MEFs and
C2C12 skeletal myoblasts stably expressing the IκBα mutant
super repressor (SR) inhibitor of NF-κB (Fig. 2e,f). Conversely,
whereas TNF typically activates NF-κB to induce gene expression,
TNF treatment of both MEF and C2C12 cells signiﬁcantly
reduced Slc8a1 expression (Fig. 2g and Supplementary Fig. 2E).
This response was speciﬁc to p65, since Slc8a1 expression was
comparable between p50+/+ and p50−/− MEFs (Supplementary
Fig. 2F). Collectively, these results support that NF-κB represses
Slc8a1.
NF-κB repression of Slc8a1 occurs through depletion of
H3K27ac. We next investigated the mechanism of Slc8a1
repression by NF-κB. Our previous studies in skeletal muscle
demonstrated that NF-κB repressed myoﬁbrillar genes through
activation of the Polycomb chromatin remodeling complex
associated protein, YY137,38. However, no signiﬁcant difference in
Yy1 expression was detected between mdxHRTΔIKKβ and
mdxIKKβf/f hearts (Supplementary Fig. 3A), suggesting that NFκB does not utilize YY1 to repress gene expression in cardiomyocytes. To explore the possibility of an alternative chromatin
remodeling mechanism, we used the UCSC Genome Browser to
examine the chromatin landscape of Slc8a1. Results identiﬁed a
putative regulatory region within the ﬁrst intron containing a
CpG island (Fig. 3a). In addition to regulating genes through
DNA methylation, CpG islands inﬂuence chromatin conformation. Accordingly, we found the CpG island embedded in a 3 kb
region, which ENCODE ChIP sequencing (ChIP-seq) datasets
also showed were enriched for numerous histone modiﬁcations.
Based on this information, we examined whether epigenetic and/
or chromatin-mediated mechanisms were regulating Slc8a1
expression by treating MEFs with the pan histone deacetylase
inhibitor (HDACi) Trichostatin A (TSA) alone, or in combination with the DNA methylation inhibitor 5-Aza-2′-deoxycytidine
(5-Aza). We ﬁrst conﬁrmed these drugs were effectively preventing histone deacetylation and demethylating DNA, respectively, using the gene, Wif1, which is epigenetically silenced in
MEFs. Wif1 was highly induced by the dual treatment of TSA and
5-Aza (Supplementary Fig. 3B). With respect to Slc8a1, TSA
increased expression, whereas 5-Aza alone had no effect (Fig. 3b).
TSA in combination with 5-Aza did not result in an additional
increase over TSA alone. Consistently, TSA increased Slc8a1
expression in HL-1 cardiomyocytes and C2C12 myoblasts
(Fig. 3c, d). Together, these results suggest that NF-κB regulates
Slc8a1 through a histone modiﬁcation-dependent mechanism.
We next performed ChIP assays to look for differences in
several histone marks. We examined the acetylation (ac) and
trimethylation (me3) of lysine 27 on histone H3 (H3K27).
H3K27ac and H3K27me3 antagonize one another, indicative of
transcriptional activation and repression, respectively. Additionally, we looked for me3 of histone H3 on lysine 9 (H3K9me3), a
mark conducive for transcriptional repression. ChIP results
revealed that Slc8a1 was enriched for H3K27ac in p65−/−
compared to p65+/+ MEFs (Fig. 3e), whereas a loss of enrichment
was detected in both H3K27me3 and H3K9me3 (Fig. 3f,g).
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H3K27ac enrichment was also detected in C2C12 SR compared to
control myoblasts (Fig. 3h). Moreover, ChIP assays revealed that
treatment of MEFs with TSA enhanced H3K27ac on Slc8a1
(Fig. 3i). To assess the signiﬁcance of our results, we performed
in vivo ChIPs. Results showed H3K27ac was depleted in
mdxIKKβf/f hearts, but was normalized in mdxHRTΔIKKβ hearts
(Fig. 3j). Together these data support that loss of NF-κB signaling
in dystrophic cardiomyocytes leads to a more permissive
chromatin conformation on Slc8a1.
NF-κB inhibition promotes global H3K27ac enrichment. To
determine if H3K27ac enrichment on Slc8a1 in the absence of
NF-κB was a global event, we performed in vivo ChIP-seq for
H3K27ac. Strikingly, ~10,000 more H3K27ac regions were
detected in mdxHRTΔIKKβ compared to mdxIKKβf/f hearts (22,498
vs 12,148), highlighting global transcriptional activation in the
absence of NF-κB signaling, and corroborating our microarray
data. Although there were ~10,000 more individual H3K27ac
regions detected in mdxHRTΔIKKβ hearts, the genomic landscape
of both our samples showed that the largest proportion of bound
regions (~77%) was within intragenic and distal intergenic
regions, which are the expected regions for an enhancer mark
such as H3K27ac (Fig. 4a). Further interrogation revealed less
than 20% of H3K27ac binding was within 10 kb of transcriptional
start sites (Fig. 4b), substantiating that enrichment was conﬁned
mostly to genomic enhancers. To characterize our H3K27ac
ChIP-seq results in the context of publicly available data sets from
the ENCODE Consortium, we examined the genome-wide coverage of H3K27ac, H3K4me1, and H3K36me3 from normal
hearts in relationship to our mdx hearts. Whereas ChIP-seq
fragment densities peaked around our data with H3K27ac and
another enhancer mark, H3K4me1, such a spike was absent in
fragment densities around peaks with H3K36me3 ChIP-seq data.
Instead, consistently elevated fragment densities occurred with
H3K36me3, an expected pattern since it marks exons throughout
actively transcribed genes (Fig. 4c and Supplementary Fig. 4A).
These data indicate the overall binding pattern we observe is
consistent with those globally expected in normal hearts.
Because we found that NF-κB suppresses genome-wide histone
acetylation, we suspected that NF-κB binding would be located
near enriched H3K27ac regions. To test this, we analyzed the
density of H3K27ac binding in our samples across peaks from a
publicly available p65 ChIP-seq data set. Results showed that
increased H3K27ac was detected surrounding p65 binding peaks
in the mdxHRTΔIKKβ hearts, even when samples were adjusted to
equalize the number of reads per experiment (Fig. 4d; total reads
and Supplemental 4B; equalized reads). Importantly, the slope of
the peak was shifted in mdxHRTΔIKKβ hearts, reﬂecting a change
in binding around these regions. These subtle differences in the
genomic landscape were expected because the observed phenotype was a change in the degree of H3K27ac, as opposed to a
complete abolishment of this activation mark. We conﬁrmed by
ChIP that p65 binding was also detected on Slc8a1 (Supplementary Fig. 4C). When differentially enriched H3K27ac regions from
mdxHRTΔIKKβ relative to mdxIKKβf/f hearts were queried for
signiﬁcant GO pathways, networks of calcium-related terms were
prominent (Fig. 4e). These ﬁndings reinforced that in the absence
of NF-κB activation, global H3K27ac is enhanced on calcium
genes of mdx hearts.
To validate ChIP-seq results, we selected a subset of calcium
genes that were also upregulated in our microarray. These genes
were Slc8a1, Rcan1 (regulator of calcineurin 1), Cacna1h (calcium
voltage-gated channel subunit alpha1 H), and Camk4 (calcium/
calmodulin dependent protein kinase IV). We conﬁrmed that
expression of these genes was upregulated in mdxHRTΔIKKβ
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relative to mdxIKKβf/f hearts (Fig. 4f). Next, ChIP analysis on all
four genes showed that H3K27ac was enriched in mdxHRTΔIKKβ
relative to mdxIKKβf/f hearts (Fig. 4g). To illustrate the
dependency of H3K27ac on NF-κB activation, we treated MEFs
with TNF. Treatment resulted in loss of H3K27ac enrichment
(Fig. 4h). Interestingly, analysis of publicly available ChIP-seq
data revealed that p65 peaks were present on all four genes near
regions where we detected H3K27ac (Supplementary Fig. 4D).
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Together, these results indicate that NF-κB orchestrates global
repression of H3K27ac in mdx hearts.
NF-κB inhibition confers permissive chromatin through
repressor redistribution. To further explore the mechanism by
which NF-κB inhibition regulates expression of calcium genes, we
performed a motif analysis using our H3K27ac ChIP-seq from
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Fig. 3 NF-κB ablation increases Slc8a1 through H3K27ac depletion. a Schematic depicting a regulatory region of interest within intron 1 of Slc8a1. Blue boxes
= exons, orange box = the region of interest, green box = CpG island, arrow = TSS. b–d Slc8a1 expression analyzed by qPCR on total RNA isolated from
b MEFs that were vehicle treated (CT) or treated with trichostatin A (TSA), 5-Aza-2′-Deoxycytidine (5-aza), or a combination of TSA and 5-aza (n = 8
except 5-aza n = 7), and c HL-1 cardiomyocytes (n = 6) or d C2C12 myoblasts treated with vehicle (CT) or TSA and expressed relative to CT expression (n
= 5 CT; 6 TSA). e–j ChIPs performed with e, h–j an H3K27ac antibody, (f) an H3K9me3 antibody (n = 3), or g an H3K27me3 antibody (n = 4) and qPCR
analysis was used to detect enrichment in the Slc8a1 regulatory region. DNA extracted from e–g, i MEFs (n = 3 e; 4 i), h C2C12 myoblasts (n = 5), or
j mouse hearts (n = 3). b–d Data expressed as means ± SEM with bars and plungers and individual data points with dots. e–j Data expressed using box and
whiskers plots. The central line in the boxes is the median value; the lower and upper boundaries of the boxes represent the lower and upper quartiles,
respectively; the lower and upper whiskers represent the minimum and maximum values, respectively. Individual data points are plotted with dots.*p < 0.05
CT, wt, or vehicle MEF, #p < 0.05 5-aza or IgG, and $ p < 0.05 mdxIKKbf/f by b 1-way ANOVA followed by Tukey multiple comparison test, by c, d 2-tailed
Student’s t test, or by e–j 2-way ANOVA followed by Tukey Post-hoc analysis

mdxHRTΔIKKβ hearts. Due to the vast coverage of acetylated
regions, it was difﬁcult to determine other factors that may be
interacting locally with NF-κB. We circumvented this issue by
searching for motifs from a data set that included only genes
containing both p65 peaks and H3K27ac regions. As expected,
the motif containing binding sites for the NF-κB family of proteins (Rel Homology Domain; RHD) was the highest ranked
motif observed (Fig. 5a). We grouped motifs into families where
possible (representative core sequences shown in Fig. 5a) and
searched for a candidate repressor protein. The highest ranked
repressor motif was CCCTC-binding factor (CTCF). The CTCF
protein that binds these motifs is capable of repressing gene
expression39. To investigate if CTCF was associated with genes
repressed in mdx hearts, we ran a ﬁltered list of H3K27ac regions
associated with genes that were de-repressed in mdxHRTΔIKKβ
hearts. 81% of the genes containing a CTCF motif were upregulated in mdxHRTΔIKKβ hearts (Fig. 5b), indicating that CTCF
may be involved in repressing gene expression upon NF-κB is
activation.
Next, we analyzed publically available CTCF ChIP-seq data
and compared it to the genome-wide coverage of p65 peaks to
investigate the global relationship between p65 and CTCF.
Impressively, p65 binding was closely associated with coverage
of CTCF, demonstrating that p65 and CTCF are mutually bound
to many gene loci (Fig. 5c). When CTCF fragment densities
around NF-κB peak centers were evaluated based on the presence
of NF-κB motifs, we found approximately 2-fold higher
sequenced fragments from the CTCF data around peaks lacking
canonical NF-κB binding sites (Fig. 5d). This more prominent
association between CTCF and non-canonical p65 binding was
not due to a greater number of total p65 peaks, since noncanonical peaks were still found near CTCF peaks after a random
normalization for the number of peaks between the two groups
was performed (Supplementary Fig. 5A).
ChIPs conﬁrmed enriched occupancy of CTCF at sites close to
the enriched H3K27ac region in mdx hearts on Slc8a1, Rcan1,
Cacna1h, and Camk4 (Fig. 5e). Importantly, CTCF occupancy
was depleted in mdxHRTΔIKKβ relative to mdxIKKβf/f hearts,
suggesting that CTCF binding was responsive to NF-κB
inhibition. We then tested CTCF binding in response to NF-κB
activation. Corroborating our results in hearts, TNF treatment
enriched CTCF binding on all four genes (Fig. 5f). However, no
reduction in CTCF binding was observed in p65−/− compared to
p65+/+ MEFs (Supplementary Fig. 5B), indicating that CTCF
binding does not require p65. These results suggest that in
response to an inﬂammatory condition, CTCF regulates chromatin interactions on calcium genes, but this regulation is not
directly mediated by NF-κB.
We then asked if repressor complexes known to reduce
H3K27ac were affected by the loss of p65. In MEFs, SIN3
transcription regulator family member A (SIN3A) and histone
deacetylase 1 (HDAC1) showed enrichment in the same regions
8

we detected differences in H3K27ac on Slc8a1, Rcan1, Cacna1h,
and Camk4 (Supplementary Fig. 5C, D). Conversely, loss of
enrichment occurred in the absence of p65. In mdxIKKβf/f hearts,
enrichment of SIN3A and HDAC1 was observed on calcium
genes (Fig. 5g,h). Except for SIN3A on Cacna1h, this enrichment
was diminished in mdxHRTΔIKKβ hearts. These data suggest that
p65 cooperates with chromatin repressors to reduce H3K27ac on
calcium genes and limit their expression. To investigate if NF-κB
was capable of antagonizing H3K27ac, we treated HL-1
cardiomyocytes with TSA and TNF. Enhanced gene expression
afforded by TSA was diminished by TNF treatment (Fig. 5i). Such
data support that upon activation, NF-κB is capable of
antagonizing H3K27ac, even in the presence of an HDACi. We
then asked if the binding of repressor complex members near p65
peaks was a global occurrence. Because our ChIP-seq was
performed with H3K27ac, we used a p65 ChIP-seq data set.
The overall binding density of SIN3A and HDAC1 was greater
surrounding p65 peaks on genes upregulated in mdxHRTΔIKKβ
hearts (Fig. 5j). Together, these data indicate that in the presence
of p65, repressive complexes occupy calcium genes, resulting in a
less permissive chromatin conformation.
Discussion
DMD is a devastating disease that adversely affects both skeletal
and cardiac muscles. However, little is known regarding the
mechanisms of cardiomyopathy, particularly when it comes to
the contribution of individual signaling pathways. Although p38MAPK is aberrantly activated in mdx hearts40, the impact of this
activation and the identity of other signaling pathways that may
contribute to DMD cardiomyopathy have not been explored.
Perhaps better understood, is that disruption of calcium homeostasis is considered causative for the pathology of dystrophic
hearts10. More speciﬁcally, a leaky sarcolemma due to the primary loss of dystrophin, activation of calcium leak channels, and
alterations in ryanodine receptor channel function, have each
been linked to altered calcium concentrations and cellular signaling. However, what causes the alterations in calcium handling
proteins and whether reversing these changes rescues dystrophic
cardiomyopathy remain unclear.
In this study, we show that inhibiting NF-κB alleviates cardiac
dysfunction in mdx mice by orchestrating global chromatin
remodeling to improve calcium signaling. In this respect, we
showed that in cardiomyocytes, p65 functions in a different
manner than its typical role of directly binding DNA and activating gene expression. Rather, in dystrophic hearts, NF-κB binds
to both its consensus and non-consensus sites, which associates
with the enrichment of CTCF on calcium genes. In these same
regions, HDAC1 and SIN3A are also enriched, resulting in loss of
H3K27ac and a less permissive chromatin conformation. In the
absence of p65, HDAC1 and SIN3A binding are reduced,
resulting in enriched H3K27ac and a more permissive chromatin
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Fig. 4 Cardiomyocyte NF-κB ablation causes global H3K27ac enrichment in mdx hearts. a Venn diagram pie chart depicting the H3K27ac ChIP-seq
annotation within speciﬁed regions of the genome from mouse hearts. b Genome-wide distribution of H3K27ac binding loci relative to transcription start
sites (TSS). c–d Genome-wide fragment density showing potential overlap of c. ChIP-seq histone marks across peaks from our ChIP-seq performed in
mdxHRTΔIKKβ hearts and d our ChIP-seqs across peaks from p65 ChIP-seq. e Network showing the top 15 Gene Ontology clusters identiﬁed from
differentially enriched genes in the mdxHRTΔIKKβ when compared to mdxIKKβf/f H3K27 regions. The most signiﬁcantly enriched pathway for each cluster is
labeled as the representative term for that group. f Gene expression analyzed by qPCR on total RNA isolated from hearts (n = Rcan1: 5 wt; 6 mdxIKKβf/f; 6
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Bars represent (g) enrichment in hearts and h depletion in TNF treated MEFs. f Data expressed using box and whiskers plots. The central line in the boxes
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represent the minimum and maximum values, respectively. Individual data points are plotted with dots. g–h Data expressed as means ± SEM with bars
and plungers and individual data points with dots. f *p < 0.05 wt and # p < 0.05 mdxIKKβf/f, by 1-way ANOVA followed by Tukey multiple comparison test.
g–h *p < 0.05 mdxIKKβf/f or untreated MEFs by 2-tailed Student’s t test
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conformation. Thus, in DMD, NF-κB inhibition alters the
enhancers of calcium homeostatic genes, which normalizes cardiac function.
NF-κB has previously been shown to interact directly with
HDAC1 where it can deacetylate p65, functionally reducing its
ability to activate gene expression41. Our data suggest that NF-κB
also interacts with HDAC1 to assist in the deacetylation of
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chromatin on calcium homeostatic genes. In addition to HDAC1,
we found that p65 interacts with SIN3A (Supplementary Fig. 5E).
This suggests that p65, SIN3A, and HDAC1 form a complex that
is responsible for the deacetylation of H3K27, and ultimately for
the transcriptional repression of calcium genes. These observations have exciting implications, as HDACi are being actively
pursued as a therapeutic for treating skeletal muscle pathology in
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Fig. 5 CTCF, SIN3A, and HDAC1 mediate a less permissive chromatin conformation on calcium genes upon NF-κB activation. a Motif analysis performed on
genes identiﬁed as having both p65 ChIP-seq peaks and H3K27ac mdxHRTΔIKKβ ChIP-seq regions. b Pie graph representing the percentage of genes with
CTCF motifs up- and downregulated in the microarray (relative to mdx hearts with intact NF-κB). c ChIP-seq data derived from genome-wide fragment
density analysis showing potential overlap of CTCF peaks with p65 peaks. d The same analysis as in c except p65 peaks were split between two groups
either containing or lacking an NF-κB consensus motif. e–f ChIP performed with a CTCF antibody and qPCR analysis was used to detect enrichment on
denoted genes. DNA extracted from e mdxIKKβf/f and mdxHRTΔIKKβ hearts (n = 4 Slc8a1; 5 Rcan1; 3 cacna1h; 2 Camk4) and (f) control and TNF treated MEFs
(n = 4 except n = 2 Camk4), g–h The same analyses were performed as in e, f. DNA extracted from mdxIKKβf/f and mdxHRTΔIKKβ hearts and ChIP performed
with a (g) SIN3A antibody (n = 3 Slc8a1 and Cacna1h (p = 0.7); n = 4 Rcan1 and Camk4) (h) HDAC1 antibody (n = 3 except n = 4 Slc8a1). e–h Enrichment
on different genes were plotted as a ratio. Dotted line represents level of enrichment equal to e, g–h mdxIKKβf/f hearts and (f) control MEFs. Bars represent
e, g–h depletion in mdxHRTΔIKKβ hearts and f enrichment in TNF treated MEFs. i Gene expression analyzed by qPCR on total RNA isolated from HL-1
cardiomyocytes (n = 4). j Heatmaps showing ChIP-seq fragment densities of SIN3A and HDAC1 surrounding p65 peaks, showing potential overlap. Left
panel includes genes upregulated and right panel includes genes downregulated in the microarray. e–h Data expressed as means ± SEM with bars and
plungers and individual data points with dots. (i) Data expressed using box and whiskers plots. The central line in the boxes is the median value; the lower
and upper boundaries of the boxes represent the lower and upper quartiles, respectively; the lower and upper whiskers represent the minimum and
maximum values, respectively. Individual data points are plotted with dots. e–h *p < 0.05 mdxIKKβf/f or untreated by 2-tailed Student’s t test. i *p < 0.05 CT
and #p < 0.05 TSA by 1-way ANOVA followed by Tukey multiple comparison test

DMD42. Although HDACi have not been tested for their ability
to improve heart function per se, they have been shown to reduce
cardiac arrhythmias in mdx mice43. In addition, a recent study
reported that administration of an HDACi to diabetic mice
resulted in improved cardiac function44, implying that if HDACi
are approved for the treatment of skeletal muscle pathology in
DMD boys, they may have the added beneﬁt of improving heart
function.
It is noteworthy that all four of the calcium homeostatic target
genes we examined were transcriptionally active in wt hearts. This
demonstrates that none of these genes are epigenetically silenced
in cardiac muscle, as we anticipated, since their expression contributes to cardiac homeostasis. We made an interesting observation when we compared the expression levels of these calcium
genes between wt and mdxIKKβf/f hearts. Although NF-κB is
activated in dystrophic hearts, we ﬁnd that NF-κB is not acting in
its canonical role as a direct transcriptional activator, but rather as
a modulator of chromatin conformation to deplete H3K27ac. We
anticipated that depletion of H3K27ac would result in reduced
expression of these calcium target genes, but this was not the case.
We speculate that this absence of repression could be due to a
compensatory response by a dystrophic heart to activate these
genes in attempt to maintain calcium homeostasis and normal
heart function. For example, transcriptional regulation of Slc8a1
was previously attributed to MAP kinases45, which are also
activated in mdx hearts40,46. Thus, it is possible that while MAP
kinase signaling is actively attempting to upregulate Slc8a1
transcription, activation of NF-κB is conferring a restricted
chromatin conformation, thus limiting access to transcription
factors downstream of MAP kinase activity that are needed to
stimulate higher Slc8a1 expression. Therefore, with NF-κB inhibition, local chromatin regains a more permissive conformation,
allowing access to transcription factors so that a compensatory
response occurs and cardiac function is maintained at wt levels. It
will be interesting in future studies to address whether the ability
of NF-κB to regulate H3K27ac and restrict chromatin conﬁrmation occurs under physiological conditions in normal cardiomyocytes, or as shown with C2C12 and MEFs, is relevant in
other non-cardiac tissues.
Although NF-κB has not been studied in depth in the context
of dystrophic cardiomyopathy, its association in various other
models of heart disease has been documented. For example, when
NEMO was conditionally deleted from non-diseased mouse
hearts, this resulted in aged related dilated cardiomyopathy and
ﬁbrosis that could be elicited in younger mice using a pressure
overload model47. These data are in stark contrast to our ﬁndings
where we observed improved function with no difference in

ﬁbrosis. These differences could be attributed to deletion of IKKβ
vs NEMO, or potentially due to the difference in phenotype when
NF-κB signaling is interrupted in a disease state (dystrophy)
rather than in a normal condition. In heart failure models,
inhibiting NF-κB has beneﬁcial effects including improved survival and function, and reduced apoptosis and hypertrophic
remodeling48–50. Additionally, one report showed that cardiomyocyte p65 deletion preserved calcium handling after ischemiareperfusion injury51. This improvement corresponded with
increased phosphorylation of serine 16 on phospholamban,
resulting in increased sarcoplasmic reticulum calcium uptake. We
too observed increased phosphorylation on phospholamban, but
perceive this post-translational modiﬁcation as a downstream
event rather than a direct result of p65 deletion since NF-κB
subunits do not possess phosphatase activity. NF-κB inhibition
also prevented the development of diabetic cardiomyopathy52.
Mice were reported to maintain normal calcium handling with no
aberrant activation of the renin-angiotensin pathway. These
ﬁndings are supportive of our conclusion that NF-κB signaling is
detrimental to the stressed heart, and that inhibiting this pathway
provides beneﬁcial outcomes.
Like NF-κB, the functions of CTCF are vast, and sometimes
contradictory. They include maintaining higher order chromatin
structure, gene insulation, maintaining borders between euchromatin and heterochromatin, X-inactivation, gene repression, and
gene activation39. We show that when NF-κB is activated, CTCF
occupies its binding sites, conferring a higher order chromatin
conformation on calcium genes that favor a repressive structure.
CTCF occupancy was not reduced in the absence of p65, indicating that although CTCF is responsive to NF-κB activation, its
binding does not require the co-binding of p65. Higher order
chromatin conformation changes due to CTCF binding has
previously been shown to occur in response to inﬂammatory
induced NF-κB activation, which is similar to what we have
shown, but how this occurred was not elucidated53. One group
reported that CTCF is a direct transcriptional target of NF-κB54.
Although this could explain why in our study CTCF binding was
reduced in the absence of NF-κB activation, in our hands CTCF
mRNA expression was unchanged in mdxHRTΔIKKβ hearts or in
p65−/− compared to p65+/+ MEFs. It therefore remains to be
determined how CTCF is regulated on calcium genes in response
to NF-κB activation.
We performed this study because there is a need to ﬁnd
effective therapeutics whose mechanism of action is understood,
and whose functions are capable of targeting both cardiac and
skeletal muscle in DMD. Through our previous genetic studies,
we identiﬁed mechanisms for how NF-κB signaling is detrimental
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to the skeletal muscles of dystrophic mice and then showed that
administration of the NBD peptide improves skeletal muscle
pathology and function in both dystrophic mice and canines. We
now add to these ﬁndings by showing a mechanism for how NFκB signaling is detrimental to dystrophic cardiac function. To our
knowledge, NF-κB represents the ﬁrst signaling pathway capable
of promoting pathology in both dystrophic cardiac and skeletal
muscle. Understanding its mode of action in both muscle types
now provides stronger rationale for targeting this pathway as a
therapeutic for DMD.
Methods
Mice. Animal use and experimentation for this study was approved by The Ohio
State University (OSU) Institutional Animal Care and Use Committee and all
experiments were performed in accordance with relevant ethical guidelines and
regulations. Mdx mice were originally purchased from The Jackson Laboratory
(C57BL/10 ScSn DMDmdx) and have been housed and bred in the animal facilities
of OSU for 10 years. Myh6 cre and IKKβ ﬂox mice were previously created55,56.
Mice were kept on a 14:10 light-dark cycle with constant temperature and humidity
and fed a standard diet. Male mice were used for these studies.
Cell culture. MEFs were previously isolated and immortalized in our lab from
p65+/+, p65−/−, p50+/+, and p50−/− mice57. C2C12 mouse myoblast cell line and
C2C12 cells stably expressing a mutant IκBα plasmid (C2C12 SR) were utilized58.
Cells were originally obtained from ATCC and cultured in high-glucose DMEM
containing 10% fetal bovine serum and antibiotics. C2C12 myoblasts were differentiated in high-glucose DMEM without sodium butyrate supplemented with 2%
horse serum, 100 ng ml−1 insulin, and antibiotics. HL-1 cardiomyocytes were
obtained from SIGMA and cultured in Supplemented Claycomb Medium. Cells
were treated with 10 ng ml−1 TNFα for 4 h (ChIP and gene expression with TSA
treatment) or 1 ng ml−1 for 2 days (gene expression with no treatment), 50 nM
TSA for 24 h (MEF and C2C12) or 48 h (HL-1), 1 μM 5-Aza for 1 passage. For
combination experiments, 5-Aza was added for one passage then MEFs were
treated with TSA for 24 h. For TSA + TNF, cells were treated with TSA for the
indicated time (see above) and then treated with TNF for the last 4 h of experiment.
Cells lines were not authenticated or tested for mycoplasma.
NBD mouse administration. NBD peptide was administered by intraperitoneal
injections18. Injections were performed three times per week for 1 month starting
at 6 months of age at a dose of 10 mg kg−1.
EMSA. Electrophoretic mobility shift assay (EMSA) and supershifts were performed using a standard protocol59. Hearts were homogenized and nuclear extracts
prepared. Extracts were incubated with a radioactive oligonucleotide containing a
consensus NF-κB binding site and fractionated on a 5% non-denaturing polyacrylamide gel. For supershifts, extracts were incubated with the following antibodies: 4 μl p50 (114 Santa Cruz) or IgG or 0.5 μl p65 (Rockland) prior to loading
on the gel.
Western blotting. Protein was extracted and immunoblotting procedures performed. Primary antibodies: phosphorylated p65 serine 536 (1:1,000, Cell Signaling
3031), p65 (1:10,000; Rockland, non-catalog item), p50 (Santa Cruz, sc-114).
Uncropped scans are available in Supplementary Fig. 6.
Tissue preparation and histology. Hearts were either snap frozen for RNA and
protein or mounted in OCT and frozen in 2-Methylbutane cooled to the temperature of liquid nitrogen. 10 μm sections were prepared on a cryostat. Histological staining was performed for H&E. Immunohistochemistry was performed
using a phosphorylated p65 serine 536 (1:500; Cell Signaling, 3031) primary
antibody, HRP goat anti-rabbit IgG (1:250, Vector, BA-1000) secondary antibody
and a DAB substrate kit (Vector, SK-4100) for detection.
Multicellular cardiac contractile function. Cardiac muscles were isolated and
baseline measures, frequency-dependent activation, and β-adrenergic stimulation
were accessed ex vivo. Under deep anesthesia, hearts were rapidly removed, and
ﬂushed with a Krebs-Henseleit solution. The right ventricle was opened, and small
papillary muscles were dissected under a stereo microscope. Muscles were mounted
in an experimental chamber and superfused with Krebs-Henseleit solution, containing 1.5 mM Ca2+, at 37 °C. Muscles were electrically stimulated to twitch
contract, and force of contraction was recorded. For baseline measurements, after
the muscle had equilibrated in the set-up, muscle length was increased until a
further increase in length no longer resulted in an increase in active twitch
developed peak force. This length was then considered optimal length. Frequencydependent stimulation (between 4 and 14 Hz), and β-adrenergic stimulation (1 nM
– 1000 nM Isoproterenol) responses were then determined. Additionally, as a
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model-independent parameter of force decay kinetics, time from peak force to 90%
relaxation (RT90), was determined.
Echocardiography. Echocardiography was performed using a VEVO 2100 Visual
Sonics (VisualSonics, Toronto) system. Mice were lightly anesthetized (1.5% isoﬂurane) and ejection fraction, fractional shortening, and ventricular chamber
dimensions were measured in M mode using the parasternal short axis view.
Left ventricular pressure-volume relationship analysis. Cardiac hemodynamic
measurements were assessed via a closed chest approach using a 1.4 French Millar
Pressure catheter (AD Instruments) advanced into the left ventricle through the
right carotid artery. Mice were anaesthetized by ketamine (55 mg kg−1) plus
xylazine (15 mg kg−1). After 5–10 min of stabilization, values at baseline and stimulation at varying frequencies (4–10 Hz) were recorded. Pressure volume loops at
7 Hz were also obtained at varying preloads via inferior vena cava occlusions to get
EDPVR, ESPVR, and PRSW. To measure the beta-adrenergic response, 5 mg kg−1
dobutamine was injected intraperitoneal. All the measurement and analysis were
performed on LabChart7 (AdInstruments).
Gene expression analysis. Total RNA was isolated using a standard Trizol
extraction protocol. 1 μg of RNA and M-MLV reverse transcriptase was used for
cDNA synthesis. Quantitative Real-time PCR was performed using SYBR Green on
either an Applied Biosystems StepOnePlus or BioRad CFX96 Touch system. All
data were normalized to gapdh and the ΔΔct method was applied for analysis.
Primer sequences are included in Supplementary Table 2.
Microarray. Total RNA was isolated using a standard Trizol extraction protocol
and puriﬁed with a cleanup kit (Qiagen). A GeneChip Mouse Genome 430 2.0
Affymetrix array was used. Gene summary expression estimates were retrieved
using Robust multi-array average (RMA) method from probe level data after back
ground correction and quantile normalization with Partek software (http://www.rproject.org/). RMA and gene expression data were also independently obtained
using Expression Console software from Affymetrix. Gene Set Enrichment
Analysis60,61 was used for further analysis.
Cardiomyocyte isolation. Cardiomyocytes were isolated by Langendorff perfusion. Hearts were cannulated and perfused with Ca2+ free tyrode solution (Normal
tyrode solution in mM: 140 NaCl, 4 KCl, 1 MgCl2, 10 glucose, and 5 HEPES, pH
7.4 adjusted with NaOH or HCl) for 5 min. Subsequently, hearts were perfused
with a tyrode solution containing Liberase Blendzyme II (0.077 mg ml−1) (Roche
Applied Science, Indianapolis, IN). After 4–6 min, hearts were removed from the
Langendorff apparatus, the ventricles minced, and myocytes dissociated via trituration. Myocytes were then ﬁltered and centrifuged before being resuspended in
a tyrode solution containing 200 μM Ca2+.
Myocyte calcium transient measurements. Myocytes were loaded with Flou-4
Am (10 μM, Molecular Probes, Eugene, OR) and incubated for 30 min. Myocytes
were then washed and allotted an additional 30 min for de-esteriﬁcation. A Cairn
Research Limited (Faversham, UK) epiﬂuorescence system was used for intracellular Ca2+ measurements (Fluo-4 epiﬂuorescence with excitation: 480 ± 20 nm and
emission: 535 ± 25 nm). The change in ﬂuorescent intensity is expressed as ΔF/F0,
where F is the ﬂuorescence intensity and F0 is the ﬂuorescence intensity at rest.
ChIP. Cells were ﬁxed with 1% formaldehyde for 8 min at 37 °C. Formaldehyde was
quenched with 1/20 volume of glycine (2.5 M), cells washed with PBS, and scraped
in nuclei isolation buffer (20 mM PIPES (KOH) pH 8.0, 85 mM KCl, 0.5% NP-40,
1x protease inhibitors). Nuclear pellets were lysed (10 mM EDTA, 50 mM Tris-HCl
pH 8.0, 1% SDS, 1x protease inhibitors) and sonicated with a probe sonicator.
Supernatant was precleared with tRNA/Protein G agarose slurry in buffer (1.2 mM
EDTA, 16.7 mM Tris-Hcl pH8.0, 167 mM NaCl, 1.1% Triton-x 100, 0.01% SDS, 1x
protease inhibitors) for 2 h then incubated overnight using the following antibodies
from Millipore: 3 μg H3K27ac (17–683 and 07–360), HDAC1 (17–10199), and IgG
(Rabbit, 12–370; Mouse, 12–371), Active Motif: 5 μg H3K9me3 (61013) and
H3K27me3 (39155), Novus: 6 μg SIN3A (600–1263), Santa Cruz: 3 μg CTCF
(5916). For tissue ChIP, sodium heparin was administered to mice prior to excising
heart. Hearts were washed in PBS, minced, then simultaneously ﬁxed and homogenized (1% formaldehyde in nuclei isolation buffer) for a total time of 15–20 min
at 4 °C. Nuclei were washed with PBS and then lysed and sonicated as described in
cells. Supernatants were precleared for 4 h and ChIP proceeded as described in cells
with the addition of a centrifugation step following overnight antibody incubation.
Quantitative Real-time PCR was performed using TaqMan (Roche) on a BioRad
CFX96 Touch system. Primer sequences are included in Supplementary Table 3.
ChIP-sequencing. ChIP was performed with a 15 μg H3K27ac antibody (17–683,
Millipore). Puriﬁed DNA (10 ng) was end-repaired, and A-nucleotide overhangs
were added by incubation with the Taq Klenow fragment lacking exonuclease
activity. After the attachment of anchor sequences, fragments were PCR-ampliﬁed
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using Illumina-supplied primers. The puriﬁed DNA library products were evaluated using Bioanalyzer (Agilent) and SYBR qPCR and diluted to 10 nM for
sequencing on HiSeq 2000 sequencer (pair-end with 50bp). A data analysis pipeline
SCS v2.5 (Illumina) was employed to perform the initial bioinformatics analysis
including base calling and converting the results into raw reads in FASTQ format.
ChIP-sequencing analysis. Bowtie2 was used to map uniquely aligned sequence
reads to the mouse reference genome (mm9)62. HOMER (Hypergeometric Optimization of Motif EnRichment) software suite was used to create tag directories, for
peak calling and annotation, for motif analysis, to create histograms, determine
differentially enriched peaks, and generate a data matrix for heatmaps63. ChIPseeker software was used to visualize genomic regions of H3K27ac binding and
binding relative to TSS64. Metascape was used to identify pathway enrichment in
differential peaks [http://metascape.org]65. Cytoscape was used to visualize the
clustered pathways66. Cluster 3.067 was used to cluster the data matrix ﬁles and
Java TreeView68 was used to visualize these data in heatmaps.
Publicly available data. The following publicly available ChIP-seq data sets were
used. 8-week old hearts were from the ENCODE Consortium produced by the Ren
lab69. H3K27ac (GSM1000093), H3K4me1 (GSM769025), H3K36me3
(GSM1000130), CTCF (GSM918756). p65 was from LPS treated bone marrow
derived macrophages (GSM611116; GSM611117). Our previous microarray was in
Ras transformed MEFs (GSE59545).
Statistics. All data were expressed as mean ± SEM. Results were analyzed by an
unpaired 2-tailed Student’s t test, 1-way ANOVA, or repeated measures 2-way
ANOVA as appropriate. Data met the requirements for performing the appropriate
test. A P value of less than 0.05 was considered statistically signiﬁcant. Statistical
analysis was performed using GraphPad Prism 6.0 software (GraphPad Software).
Samples sizes were estimated based on previous studies. All samples represent
biological replicates. Representative western blots and EMSAs were repeated twice.
For mouse studies, data were excluded if values could not be obtained from the
sample or equipment malfunction prevented obtaining data. Randomization was
not used. For physiology experiments, the investigator was blinded to the group
being analyzed.
Data availability. The data that support the ﬁnding of this study are available from
the corresponding author on request. Microarray and ChIP-seq data have been
deposited into the GEO database under accession code GSE114026. SubSeries:
GSE114023 and GSE114025.
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